UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd.

Core Viewpoint - UroGen Pharma Ltd. is facing allegations related to misleading statements about its lead pipeline product, UGN-102, during the class period from July 27, 2023, to May 15, 2025, which may impact the company's stock and investor confidence [2]. Group 1: Allegations and Legal Context - The complaint alleges that the ENVISION clinical study was not designed to provide substantial evidence of UGN-102's effectiveness due to the absence of a concurrent control arm [2] - UroGen is accused of failing to heed FDA warnings regarding the study design, which raises concerns about the approval of the New Drug Application (NDA) for UGN-102 [2] - The allegations suggest that the company's positive statements about its business and prospects were materially misleading and lacked a reasonable basis [2] Group 2: Shareholder Actions and Deadlines - Shareholders who purchased URGN shares during the specified class period are encouraged to register for potential lead plaintiff appointment, with a deadline set for July 28, 2025 [3] - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [3] - There is no cost or obligation for shareholders to participate in this class action [3] Group 3: Law Firm's Role - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [4] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4]